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IMPORTANCE Maintenance therapies are often considered as a therapeutic strategy in
patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT)
to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel
drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is
increasingly limited. The American Society for Blood andMarrow Transplantation (ASBMT),
Center for International Blood andMarrow Transplant Research (CIBMTR), and European
Society for Blood andMarrow Transplantation (EBMT) jointly convened an expert panel with
diverse expertise and geographical representation to formulate consensus recommendations
regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients
with lymphoma.
OBSERVATIONS The RAND-modified Delphi method was used to generate consensus
statements where at least 75% vote in favor of a recommendation was considered as
consensus. The process included 3 online surveys moderated by an independent
methodological expert to ensure anonymity and an in-personmeeting. The panel
recommended restricting the histologic categories covered in this project to Hodgkin
lymphoma (HL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and
follicular lymphoma. On completion of the voting process, the panel generated 22 consensus
statements regarding post auto-HCTmaintenance and/or consolidation therapies. The grade
A recommendations included endorsement of: (1) brentuximab vedotin (BV) maintenance
and/or consolidation in BV-naïve high-risk HL, (2) rituximabmaintenance in MCL undergoing
auto-HCT after first-line therapy, (3) rituximabmaintenance in rituximab-naïve FL, and (4) No
post auto-HCTmaintenance was recommended in DLBCL. The panel also developed
consensus statements for important real-world clinical scenarios, where randomized data are
lacking to guide clinical practice.
CONCLUSIONS AND RELEVANCE In the absence of contemporary evidence-based data, the
panel found RAND-modified Delphi methodology effective in providing a rigorous framework
for developing consensus recommendations for post auto-HCTmaintenance and/or
consolidation therapies in lymphoma.
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H igh-dosetherapy(HDT)andautologoushematopoieticcelltransplantation (auto-HCT) is considered standard treat-ment for defined indications in classic Hodgkin lym-
phoma(cHL)andnon-Hodgkin lymphoma(NHL).1,2Accordingtothe
Center for International Blood and Marrow Transplant Registry
(CIBMTR) and European Society for Blood and Marrow Transplan-
tation (EBMT), in 2016 approximately 14 000 patients with lym-
phoma received auto-HCT across North America and Europe.3,4
Auto-HCT can provide durable disease control in a subset of pa-
tients. Disease relapse remains the most common cause of death
in patients with lymphoma after undergoing HDT. Most relapse
events occur within the first 1 to 3 years following auto-HCT, pro-
viding a rationale for post-HCT maintenance and/or consolidative
strategies to mitigate relapse risk.5-8
In recentyears, the lymphomatherapeutic landscapehasbeen in
flux,with thedevelopmentof several novel therapies suchasmono-
clonalantibodies (naked,conjugatedwithdrugs,bi-specificT-cell en-
gagers,etc), targetedagents(immunomodulators,proteasomeinhibi-
tors, Bruton's tyrosine kinase inhibitors, etc), and immune therapies
(checkpoint inhibitors, immuneeffectorcellsetc.) thatarerapidlyfind-
ing theirway from the relapsed or refractory to the frontline setting.
Consideringthetime involved indesigningandexecutingclinical trials
and procuring regulatory approvals, it is not surprising that studies
evaluatingmaintenanceand/orconsolidationstrategiesafterauto-HCT
have not been able to keep pacewith drug development in lympho-
mas. This unfortunatelymeans that some trials evaluating post-HCT
maintenancestrategiesinlymphomasenrolledpatientpopulationsthat
areincreasingly lessrelevanttocurrentpractice(eg,rituximab-orbren-
tuximabvedotin [BV]-naïvepatientsprior toauto-HCT).5,6Moreover,
theoff-label,off-protocoluseofapprovedantilymphomadrugsafter
auto-HCTasmaintenanceand/orconsolidationtherapies isanincreas-
inglycommonpractice.Clinicalpracticerecommendationsorconsen-
susstatementsaddressingthecontemporaryroleofmaintenanceand/
orconsolidationtherapiesafterauto-HCTinpatientswith lymphomas
arenot available. Therefore, theAmericanSocietyofBloodandMar-
rowTransplantation (ASBMT),CIBMTR, andEBMTundertooka joint
project to formulate consensus recommendations regarding theuse
ofpost–auto-HCTmaintenanceand/orconsolidationtherapies incHL
andNHL. In addition to providing recommendations for postautolo-
goustransplantmaintenanceand/orconsolidationinlymphomaonsce-
narioswhereprospectivedataareavailable, thepanelalsodeveloped
consensus statements for a number of important clinical scenarios
where randomizeddata are lacking.
Methods
Panel Composition
The development of practice recommendations was approved by
ASBMT, CIBMTR, and EBMT, the 3 leading international organiza-
tions in the field ofHCT. As an initial step, a steering committeewas
formedcomprising6members includingaproject coordinator, rep-
resentatives of ASBMT, EBMT, CIBMTR, and an independentmeth-
odologist with expertise in systematic reviews, meta-analysis, and
theRAND-modifiedDelphimethod.Thesteeringcommitteewas re-
sponsible for drafting the protocol, initial draft of consensus state-
mentsbasedonsystematic reviewof the literatureandclinical prac-
ticeconsiderations, andsettingupof theexpertpanel.9Theaimwas
to put together a panel with a balanced distribution of lymphoma
and transplant experts, tohavebroadexpertise and to cover awide
spectrum of views, while keeping administrative efforts manage-
able as previously recommended.10,11 The panel of experts con-
sisted of physicians with diverse geographical representation and
expertise in the field, asdemonstratedby their track recordofpeer-
reviewedpublications, leadershipofclinical trials relevant to thecon-
sensus project, and by their involvement in national and interna-
tional lymphomaor transplantorganizations. Inaddition, aphysician
representingacommunitypracticewas included in thepanel aspre-
viously recommended (S.A.A.).9 The final consensus panel con-
sistedof 26physicians and investigators, includingmembersof the
steering committee, except the (nonclinical) independentmethod-
ologist, who did not vote on the recommendations (A.K.).
ConsensusMethodology
The RAND-modified Delphi methodwas used to generate consen-
sus statements addressing the role ofmaintenance and/or consoli-
dation therapies after auto-HCT in lymphoma patients, as recom-
mended by the American Society of Clinical Oncology (ASCO).9-12
In the Delphi method, the participants rate the statements anony-
mously in at least 2 rounds of evaluations. In the modified version
of themethod, a face-to-facemeeting with presentation of the re-
sults precedes the second round of rating.9-11 Details regarding the
systematic step-by-step approach that was involved in this proj-
ect, are illustrated in eTable 1 in the Supplement.
After the panel selection, a baseline demographics and scope
survey was developed to determine the scope of the project. Par-
ticipantswere invitedtosubmit theirsuggestionsregardingthescope
of the consensus project andprovide input about the clinical issues
relevant to practice (eAppendix in the Supplement). After finaliza-
tion of the scope of the consensus project, the steering committee
conducted a systematic review of the literature to obtain and ex-
amine relevant evidence and thereby formulate preliminary con-
sensusstatements for the first roundofvoting (eAppendix;eTable2;
eFigure 1; and eFigure 2 in the Supplement).
The first voting survey included22consensus statementsalong
with supporting evidence (if available). Panel members rated each
statementelectronically.Thesteeringcommitteemethodologistana-
lyzed and summarized the results, while keeping the individual rat-
ings anonymous. The results of first voting survey, along with the
statementsnot reaching the thresholdof consensus (defined in sec-
tion below) were presented at the in-person meeting held in con-
junctionwith the2018ASBMTandCIBMTRTandemMeetingsatSalt
LakeCity,Utah. Consensus statements thatmet thepredefined cri-
teria for formal consensuswere recommended for approval. State-
ments that failed to achievepredefined criteria for consensuswere
discussedduringthemeetingandbasedonthediscussionsthestate-
ments were modified for revoting or dropped. The discussion also
led to the addition of 1 new statement. The second voting survey
was sent to all the panelmembers for rating of the reformulated or
newly added statements.
All surveyswereadministeredonlineusinghttp://www.qualtrics.
com (Qualtrics LLC, Provo) and results were reviewed and collated
independentlybythemethodologicalexpert.Ateachstepof thepro-
cess, the electronic survey also allowed the participatingmembers
to providewritten feedback and comments about each statement.
Collated results were shared via email with the consensus panel
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members in real timeaftereachstepwascompleted toensure trans-
parencyof theprocess.The final consensusstatementsweregraded
based on the strength and level of supporting evidence, according
to theAgencyofHealthcareResearchandQuality (AHRQ)grading.13
Definitions
During the votingprocess, statements forwarded to the consensus
panelwere ratedona5-point Likert scale (strongly agree = 1; some-
what agree = 2; neutral = 3; somewhat disagree = 4; and strongly
disagree = 5).9Aspecific statementwasdefinedashavingachieved
formal consensus, if at least 75% of the panel members voted to
strongly agree or agree to the proposed statement.
Results
Member Participation
eTable 3 in the Supplement describes the baseline characteristics
of consensus panel. Included were transplant physicians (>75% of
practice time inHCT),nontransplantacademicphysicians,mixedcli-
nicians, and a community-based clinician. Amixedpracticewasde-
finedascliniciansdevotingapproximately50%ofclinical timetoHCT
andnontransplant-related lymphoma,each. Ingeneral, panelistpar-
ticipationandresponserateswereexcellent (eFigure3 in theSupple-
ment). At the steering committee level complete participationwas
noted except for the teleconferencewhere 5 of 6members partici-
pated.During thevotingprocess, 100%participationwasnoted for
the baseline demographics and scope, first voting and second vot-
ing surveys. The in-personmeetingwasattendedby 12members in-
cluding 1memberwhocalled in. Twoadditionalmembers unable to
attend in person provided written feedback in advance.
First Voting Survey
The firstvotingsurveyconsistedof22statements specific to the role
ofmaintenanceand/orconsolidation therapiesafterauto-HCT in the
following lymphomahistologies;cHL(6statements),mantlecell lym-
phoma(MCL,8statements), diffuse largeB-cell lymphoma(DLBCL,
3 statements), and follicular lymphoma (FL, 5 statements). All but
6 statements (cHL = 3,MCL = 2, andFL = 1) achievedconsensusby
predefinedcriteria (eTable5 in theSupplement). In addition toelec-
tronically sharingwithall panelmembers, the resultsof the first vot-
ing survey were also presented at the in-person meeting. The 16
statements meeting the preset definition of consensus were re-
viewed and approved unanimously. Next, the 6 statements not
achievingconsensus (<75%agreement)during theprior votingpro-
cess were reviewed. The ensuing discussion resulted in 1 state-
ment regardingcHLbeingabandonedandallotherstatementsbeing
revised. In total 6 statements were proposed (reformulated state-
ments = 5,newstatement = 1; cHL = 2,MCL = 3, FL = 1) for the sec-
ond voting survey. eTable 6 in the Supplement shows outcomes of
the in-personmeeting.
Second Voting Survey
All statements included in the second voting survey (reformulated
statements = 5, newstatement = 1),met thepredefinedcriteria for
consensus (eTable 7 in the Supplement). The final consensus rec-
ommendations onmaintenance and/or consolidation therapies af-
ter auto-HCT in patients with lymphoma consisting of 22 consen-
sus statements are shown in Table 1 (cHL = 5), Table 2 (MCL = 9),
and Table 3 (DLBCL = 3, FL = 5).
Discussion
In clinical scenarios where data from prospective studies are
either scarce or unavailable, or in situations where therapeutic
advances or new drug indications make patient populations
included in published trials less relevant to contemporary clinical
practice, formal consensus recommendations can be an invalu-
able resource in informing clinical decision making. Expert opin-
ions and recommendations in the form of review articles and
treatment guidelines, although useful, lack methodological clarity
and may be subject to bias. In contrast, formulation of expert rec-
ommendations using established approaches, such as the RAND-
modified Dephi method, provides a formal, reproducible, and sys-
tematic process.9,11 In this project a broadly representative panel
Table 1. Final Clinical Practice Guidelines Consensus Statements
onMaintenance Therapy After High Dose Therapy and Autologous
Hematopoietic Cell Transplantation for Hodgkin Lymphoma
Consensus Statements:
Hodgkin Lymphoma
Grading of
Recommendationsa
Panelists in
Agreement,
% (n=26)
1. The panel recommends
post–autologous HCT consolidation/
maintenance with BV for 16 cycles in
BV-naïve classic Hodgkin lymphoma
(HL) with at least 1 or more high-risk
features as defined by the AETHERA
studyb
A 92
2. The panel does not recommend
postautologous HCT consolidation/
maintenance with BV for HL with prior
evidence of disease refractory to BV
C 96
3. The recommended duration of
post–auto-HCT BV consolidation/
maintenance therapy is for a maximum
of 16 cycles every 3 weeks as described
in AETHERA trial, or until unacceptable
toxicity or disease relapse/progression
(whichever occurs first)b
A 100
4. The panel recommends
post–autologous HCT consolidation/
maintenance with BV in HL with one or
more high-risk features as defined by the
AETHERA trial and limited prior
exposure to BV (approximately 4-6
cycles) preceding the autologous HCT,
but without any evidence of BV
refractory disease
C 100
5. Sufficient data do not exist to use the
preautologous-HCT PET (or PET/CT)
scan status to guide the use of
post–autologous HCT consolidation/
maintenance therapy with BV for HL
with one or more high-risk features as
defined by AETHERA Trial
C 84
Abbreviations: BV, brentuximab vedontin; HCT, hematopoietic cell
transplantation; HL, Hodgkin lymphoma; PET/CT, positron emission
tomography/computed tomography.
a Agency of Healthcare Research and Quality (AHRQ) grading of
recommendations based on level of evidence13: A, there is good
research-based evidence to support the recommendation; B, there is fair
research-based evidence to support the recommendation; C, the
recommendation is based on expert opinion and panel consensus; and X,
there is evidence of harm from this intervention.
bConsensus statement based on observed PFS benefit, but no OS benefit in
randomized clinical trials.
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Table 2. Final Clinical Practice Guidelines Consensus Statements
onMaintenance Therapy After High-Dose Therapy and Autologous
Hematopoietic Cell Transplantation forMantle Cell Lymphoma
Consensus Statements:
Mantle Cell Lymphoma
Grading of
Recommendationsa
Panelists in
Agreement,
% (n=26)
1. Regarding upfront autologous HCT for
chemosensitive MCL after 1 line of prior
rituximab and cytarabine-containing
therapy, the panel recommends
maintenance therapy with rituximab every
2 months for 3 yb
A 96
2. Regarding upfront autologous HCT for
chemosensitive MCL, the panel
recommends maintenance therapy with
rituximab (every 2 months for 3 y),
regardless of the type of pretransplant
induction treatment
B 92
3. Regarding upfront autologous HCT for
MCL with a pretransplantation PET (or
PET/CT) scan of Deauville score of 1-3, the
panel recommends postautologous HCT
rituximab maintenance therapy
C 96
4. Regarding upfront autologous HCT for
chemosensitive MCL with no evidence of
pretransplant minimal residual disease by
PCR or next-generation sequencing, the
panel recommends maintenance therapy
with rituximab
Cb 77
5. Recommended duration of
postautologous-HCT rituximab
maintenance therapy in MCL is every 2 mo
for a maximum of 3 years as described in
LYSA trial, or until unacceptable toxicity or
disease relapse/progression (whichever
occurs first)b
A 92
6. After autologous HCT for MCL,
maintenance/consolidation therapy with
agents other than rituximab (eg,
bortezomib, lenalidomide, BTK inhibitors,
BCL2 inhibitors, etc) should only be
offered in a clinical trial
C 100
7. The panel does not recommend
postautologous HCT rituximab
maintenance/consolidation for
rituximab-resistant MCL (ie, relapse or
progression of MCL while on, or within 6
mo of receiving a rituximab-containing
treatment regimen)
C 88
8. Regarding MCL patients undergoing a
delayed autologous HCT who have not
received rituximab maintenance previously
and have demonstrated no evidence of
rituximab resistance, the panel
recommends postautologous HCT
maintenance therapy with rituximab
C 100
9. Regarding patients with MCL
undergoing a delayed autologous HCT who
have previously received rituximab
maintenance but have demonstrated no
evidence of rituximab resistance, the panel
recommends postautologous HCT
maintenance therapy with rituximab
C 96
Abbreviations: HCT, hematopoietic cell transplantation; MCL, mantle cell
lymphoma; PET/CT, positron emission tomography/computed tomography.
a Agency of Healthcare Research and Quality (AHRQ) grading of
recommendations based on level of evidence13: A, there is good
research-based evidence to support the recommendation; B, there is fair
research-based evidence to support the recommendation; C, the
recommendation is based on expert opinion and panel consensus; and X,
there is evidence of harm from this intervention.
bConsensus statement based on overall survival benefit seen in randomized
clinical trials.
Table 3. Final Clinical Practice Guidelines Consensus Statements
onMaintenance Therapy After High-Dose Therapy and Autologous
Hematopoietic Cell Transplantation for Diffuse Large B-cell
and Follicular Lymphoma
Consensus Statements: Diffuse Large B-Cell
Lymphoma and Follicular Lymphoma
Grading of
Recommendationsa
Panelists in
Agreement,
% (n=26)
Diffuse Large B-Cell Lymphoma
1. The panel does not recommend
postautologous HCT maintenance therapy
with rituximab for relapsed or refractory
DLBCL that is sensitive to rituximab-based
salvage approaches
A 100
2. Regarding autologous HCT for high-risk
DLBCL (high-risk IPI score, double or triple
hit, double expressor, and/or those with
failure of first-line therapy within 1 y of
diagnosis), either in the upfront or relapsed
or refractory setting, the panel does not
recommend postautologous HCT
maintenance/consolidation therapy with
rituximab
C 100
3. Regarding autologous HCT for DLBCL,
maintenance/consolidation therapy with
novel agents (eg, monoclonal antibodies
other than rituximab, bortezomib,
lenalidomide, BTK inhibitors, BCL2
inhibitors, cellular therapies, etc) should
only be offered in a clinical trial
C 100
Follicular Lymphoma
1. The panel recommends postautologous
HCT maintenance therapy with rituximab
(375 mg/m2 every 2 mo for 4 doses) for
chemosensitive, relapsed,
rituximab-naïve FLb
A 81
2. The panel recommends postautologous
HCT maintenance therapy with rituximab in
high-risk FL with early therapy failure (ie,
relapse or progression of disease within 24
mo of diagnosis) and no evidence of
rituximab resistance
C 77
3. The panel does not recommend
postautologous HCT maintenance therapy
with rituximab for rituximab-resistant FL
(ie, relapse or progression of FL while on or
within 6 mo of receiving a rituximab-based
treatment regimen or single agent
rituximab)
C 92
4. Regarding autologous HCT for FL,
maintenance and/or consolidation therapy
with novel agents (eg, monoclonal
antibodies other than rituximab,
bortezomib, lenalidomide, PI3K inhibitors,
BCl2 inhibitors, etc) should only be offered
in a clinical trial
C 100
5. Acknowledging the lack of prospective
data, the panel recommends
postautologous HCT maintenance therapy
with rituximab in chemosensitive, relapsed,
previously rituximab (or other CD20
antibody)-treated FL, without any prior
evidence of rituximab resistance
B 84
Abbreviation: DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma;
HCT, hematopoietic cell transplantation; IPI, International Prognostic Index;
PET/CT, positron emission tomography/computed tomography.
a Agency of Healthcare Research and Quality (AHRQ) grading of
recommendations based on level of evidence13: A, there is good
research-based evidence to support the recommendation; B, there is fair
research-based evidence to support the recommendation; C, the
recommendation is based on expert opinion and panel consensus; and X,
there is evidence of harm from this intervention.
bConsensus statement based on overall survival benefit seen in randomized
clinical trials.
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of lymphoma and transplant experts with diverse practice experi-
ence and geographical representation, endorsed by ASBMT,
EBMT, and CIBMTR, was formed to provide consensus recom-
mendations on the role of maintenance and/or consolidation
therapies after auto-HCT in lymphomas. It should be noted that
most panel members practiced in academic settings (96%) and
were transplant physicians with or without non-HCT lymphoma
practices, which could be a potential source of confirmation bias.
Considering the limitations in existing data and the rapidly
expanding repertoire of therapeutic options in lymphoma, such
an undertaking was considered a priority and addresses a gap in
existing literature. A systematic literature search and expert input
identified the gaps in current knowledge and aided the formula-
tion of statements aimed at addressing them. Reported here are
22 practice recommendations addressing the role of maintenance
and/or consolidation therapies after auto-HCT in patients with
lymphoma (cHL = 5, MCL = 9, DLBCL = 3, FL = 5) (Tables 1-3).
Fiveconsensusstatementsweregeneratedregardingpostauto-
HCT maintenance/consolidation therapy in cHL. Taking into ac-
count the results of theAETHERA trial,6 thepanel recommendsBV
maintenance/consolidationafterauto-HCT inpatientswithcHLwho
have 1ormore trial-specified risk factors (ie, primary refractory cHL,
relapsedcHLwith an initial remissiondurationof <12months, or ex-
tranodal involvementat the start ofpretransplantation salvageche-
motherapy) at 1.8 mg/kg intravenously every 3 weeks for 16 doses
inBV-naïvepatientswith cHL. The consensuspanel considered the
fact that presence ofmore than 1 risk factor, per AETHERA trial cri-
teria, may be associated with additive deleterious effects on pa-
tientoutcomes.Forexample,aCIBMTRreportshowedthat theprog-
nosis of patients with cHL who had multiple (AETHERA-like) risk
factors was poor.14 Similarly, a post hoc analysis of the AETHERA
study suggested that patientswith cHLwhohad 2 ormore risk fac-
torsderivedgreaterprogression-free survival (PFS)benefit fromBV
maintenanceafter auto-HCT.6The facts that routineuseofBVmain-
tenanceand/orconsolidationhasnotbeenshownto improveOSand
that it may be associated with higher US health care costs com-
paredwith surveillancealone,werealsoconsidered.15However, the
panel decided to drop the proposed statement limiting use of BV
maintenanceand/or consolidation topatientswithmore than2 risk
factors (eTable 6 in the Supplement), owing to the lack of high-
quality evidence supporting this restriction.Of note, theAETHERA
trial only enrolled BV-naïve patientswith cHL.With the approval of
BV in the frontline setting16 and increasing use of this agent in pre–
auto-HCT salvage regimens,17-20 the number of patientswith high-
risk cHLwhohave prior BV exposure is likely going to increase. The
panel discussed this important real-world clinical scenario, where
high-quality prospective data are not available, underscoring the
need for consensus recommendations. Accordingly, the panel rec-
ommended the use of BVmaintenance and/or consolidation in pa-
tients with prior limited exposure to BV (defined as approximately
4-6 cycles), undergoing auto-HCT who otherwise meet the
AETHERA risk criteria and did not demonstrate prior resistance or
intolerance to BV. The panel acknowledge that “limited prior expo-
sure” in our statement is empirical but agreed to include it as a con-
sideration because no data are available to suggest a benefit asso-
ciated with BV maintenance and/or consolidation in patients with
priorprolongedexposure to this agent. Preautograft positronemis-
sion tomography (PET) scan status is an important determinant of
patient prognosis.21 The panel deliberated the possibility of a PET-
based risk-adapted approach in recommending BV maintenance
and/orconsolidation therapyafterauto-HCT(eTable6 in theSupple-
ment). Because no robust data are available to show lack of benefit
with BV maintenance and/or consolidation in patients with PET-
negative high-risk cHL, the panel concluded that sufficient data do
not exist to use the pretransplant PET (or PET/CT) scan status to
guide the use of BV maintenance and/or consolidation therapy af-
ter auto-HCT.
In patientswithMCLundergoing upfront auto-HCT after ritux-
imab and cytarabine-containing induction, a randomized trial7
showed improvedPFSandoverall survival (OS)with rituximabmain-
tenance comparedwithobservation. Thiswas in linewith anearlier
retrospective study.22 Based on these results, the panel achieved
consensus to recommendmaintenance rituximab every 2 months
for amaximumof 3-year (or until unacceptable toxic effects or dis-
ease relapseorprogression [whicheveroccurs first]) inpatientswith
MCL undergoing upfront auto-HCT consolidation following induc-
tion with rituximab and cytarabine-based therapy. The panel ac-
knowledged that the efficacy of rituximabmaintenance (at least in
transplant noneligible patients), is dependent on the type of front-
line therapy, where the benefit is more pronounced after R-CHOP
induction, andmaybe lacking following fludarabine- or bendamus-
tine-based approaches.23,24 With this limitation in mind, the panel
did reach consensus to recommend maintenance rituximab in pa-
tients with MCL undergoing upfront auto-HCT consolidation, re-
gardless of the induction regimen received (grade, C; grading de-
fined in footnote of Table 2), and in patients with MCL undergoing
delayed auto-HCT (butwithout any prior evidence of rituximab re-
sistance [grade,C]).Weacknowledge that thereareonly limited ret-
rospective data that support these statements,25 and that these
statements in large part reflect expert consensus (grade, C recom-
mendation). No data exist to use pretransplant PET or minimal re-
sidual disease (MRD) status in determining the need for mainte-
nance rituximab in patients with MCL undergoing auto-HCT.
Considering the OS benefit associated with rituximab mainte-
nance in the LYMA trial,7 the panel reached a consensus to recom-
mendmaintenance even in PET or MRD-negative patients. We ac-
knowledge that in MRD-negative patients, monitoring and
preemptive rituximab therapy in those with molecular relapse has
been shown to induce subsequent molecular responses26; how-
ever, no data exist to show if this preemptive approach is compa-
rable (better, or inferior) to rituximabmaintenance.Of note, the re-
cently activatedUS Intergroup trial (NCT03267433) is randomizing
MRD-negativepatientswithMCLtoauto-HCTornoauto-HCT. In this
study all MRD-negative patients irrespective to study arm, will re-
ceive rituximabmaintenance for 3 years.
In DLBCL, consensus was achieved to not recommend ritux-
imabmaintenance after auto-HCT in relapsed or refractory DLBCL
thatwassensitivetorituximab-basedsalvageapproaches.Theserec-
ommendations are supported by the final analysis of the CORAL
study,8 which showed no event-free survival improvement associ-
atedwithmaintenance rituximabcomparedwithobservation. Simi-
larly, the panel did not endorse maintenance and/or consolidation
therapies in patientswith high-riskDLBCL (basedon either clinical,
histologic, or genomic criteria). Although lenalidomide has been
shown to improve PFS in elderly patients with DLBCL after front-
linetherapy,27nodataareavailable tosupports itsusefollowingauto-
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HCT. An ongoing randomized, intergroup trial is comparing ibruti-
nib vs placebo after auto-HCT in activated B-cell subtype of DLBCL
(NCT02443077)andmayclarify theroleofmaintenanceand/orcon-
solidation therapy guided by cell-of-origin.
In FL, the panel endorsed rituximab maintenance after auto-
HCT for chemosensitive, relapsed, rituximab-naïve patients, pri-
marily basedon theEBMTstudy findings (grade, A).5However, the
panel acknowledges that rituximab-naïve statusat the timeof auto-
HCT in patients with FL in the current era would be rare, thus limit-
ing the clinical impact of this statement. Although patients with FL
receiving other CD20 antibodies before auto-HCT (eg, obinu-
tuzumab)butnot rituximabarearguably rituximab-naïve, thepanel
cautions against extrapolating the above recommendation to this
population, especially because the toxic effects profile of ritux-
imabmaintenanceafterpriorobinutuzumabexposure isnotwellde-
fined. This scenario is relevant given the survival benefit associ-
atedwithobinutuzumab in the relapsed (PFS andOS) and frontline
(PFS) settings.28,29 For the clinically more relevant, rituximab-
treated patients with FL, no prospective data for the use of main-
tenance rituximabafter auto-HCTexist. Limited retrospectivedata
in this setting suggest improved3-yearPFS (86%vs46%,P = .004)
anda trend toward improvedOS (96%vs78%,P = .06)withmain-
tenance rituximabcomparedwithobservation.30 Inaddition, apro-
spective trial as well as an individual patient data meta-analysis
showed that rituximabmaintenance improvedPFSandOS, respec-
tively, in rituximab-pretreated patients outside the transplant
setting.31,32 However, although the panel recommended rituximab
maintenance in previously rituximab (or other CD20 antibody)-
treated patients with FL (without any prior evidence of rituximab
resistance), the lackofqualitydata supporting this consensus state-
ment is also clearly acknowledged (Table 3). Early failure of chemo-
immunotherapy (within 2 years) identifies patients with FL with a
poorprognosis.33Recent retrospectivedata suggest improvedout-
comes in a subset of such patients with auto-HCT34-36 but disease
relapse remainscommon. In thischallengingsubset, rituximabmain-
tenancewas recommendedwith thecaveat thatpatients shouldnot
be rituximab refractory.
Thepanel unanimously voted todiscourage theoff-label useof
novel agents as maintenance and/or consolidation therapies after
auto-HCT and recommend such use only in the context of a clinical
trial. Throughout the consensus project we adopted a commonly
used definition of rituximab resistance (ie, evidence of relapsed or
resistant or progressive disease while taking or within 6months of
receivinga rituximab-based regimen). Thisdefinition, although rou-
tinely used, has the inherent limitation that it cannot distinguish
whether the disease is truly resistant to rituximab or to the accom-
panying chemotherapy agents (in patients getting rituximab with
chemotherapy).We also acknowledge that these consensus state-
mentsarenotasubstitute forprospectivecontrolleddata,butmainly
aim to provide guidance where gaps in knowledge exist. The dura-
tion of maintenance after auto-HCT recommended in the consen-
susstatements isbasedonavailableprospectivedata,however,early
cessationofmaintenance shouldbe considered for intoleranceand
toxic effects.Disease relapse continues to remain the leading cause
of postauto-HCT mortality. With changes in the therapeutic land-
scapeof lymphoma treatment, incorporationof novel agents in the
peri-HCTperiod tomitigate the riskof therapy failure remains anat-
tractive but underinvestigated option.
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